Share on StockTwits

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) were the target of a large growth in short interest in the month of June. As of June 13th, there was short interest totalling 21,842,028 shares, a growth of 10.1% from the May 30th total of 19,832,470 shares, reports. Approximately 26.3% of the shares of the company are sold short. Based on an average daily volume of 18,891,416 shares, the days-to-cover ratio is currently 1.2 days.

In other Achillion Pharmaceuticals news, Insider Ra Capital Management, Llc sold 880,000 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $8.40, for a total transaction of $7,392,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Wells Fargo & Co. raised their price target on shares of Achillion Pharmaceuticals to $8.00 in a research note on Monday, June 23rd. Separately, analysts at Maxim Group raised their price target on shares of Achillion Pharmaceuticals from $6.00 to $22.00 in a research note on Monday, June 16th. They now have a “buy” rating on the stock. Finally, analysts at Robert W. Baird upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 11th. They now have a $12.00 price target on the stock, up previously from $4.00. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.74.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 7.45 on Monday. Achillion Pharmaceuticals has a 52 week low of $2.26 and a 52 week high of $8.61. The stock has a 50-day moving average of $4.45 and a 200-day moving average of $3.60. The company’s market cap is $721.1 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. On average, analysts predict that Achillion Pharmaceuticals will post $-0.77 earnings per share for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.